title: [Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
abstract: The effects of ondansetron hydrochloride (OND) were studied through 11 courses of chemotherapy, including 70 mg/m2 of cisplatin, in 9 patients with advanced esophageal cancer. During the observation period of 5 days, 4 mg of OND was given intravenously on the day of cisplatin infusion and orally for consecutive 4 days, and nausea was controlled by over 70%. Vomiting was controlled by over 80%. The inhibitory effect of OND on nausea and vomiting was found in 72.7% on the day of cisplatin injection and 88.9% overall. No other side effects of OND except slight increases in total bilirubin and LDH were found in any patient. These findings suggest that intravenous and oral administration of OND may inhibit chemotherapy-induced nausea and vomiting in patients with advanced esophageal cancer.
authors.affiliation: First Dept. of Surgery, Nippon Medical School.
authors.forename: M
authors.initials: M
authors.lastname: Miyashita
authors.forename: M
authors.initials: M
authors.lastname: Onda
authors.forename: K
authors.initials: K
authors.lastname: Ikeda
authors.forename: K
authors.initials: K
authors.lastname: Bando
authors.forename: N
authors.initials: N
authors.lastname: Hagiwara
authors.forename: Y
authors.initials: Y
authors.lastname: Tsuchiya
authors.forename: T
authors.initials: T
authors.lastname: Yoshiyuki
authors.forename: T
authors.initials: T
authors.lastname: Kiyama
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: K
authors.initials: K
authors.lastname: Sasajima
authors.forename: K
authors.initials: K
authors.lastname: Yamashita
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000932:Antiemetics / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007275:Injections, Intravenous; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D017294:Ondansetron / Q000008:administration & dosage*; D014840:Vomiting, Anticipatory / Q000188:drug therapy*
chemical_list: D000932:Antiemetics; D017294:Ondansetron; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil